# Bone and Body Comp: A Sub Study of the SECOND-LINE Study

> **NCT01513122** · PHASE4 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 210 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Lopinavir / ritonavir
- **DRUG:** 2-3N(t)RTI
- **DRUG:** raltegravir

## Key facts

- **NCT ID:** NCT01513122
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-09
- **Final completion:** 2013-08
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513122, "Bone and Body Comp: A Sub Study of the SECOND-LINE Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01513122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*